Aredia Articles
FDA finds no AF link for bisphosphonates
24 November 2008
FDA warns: severe pain with bisphosphonates
14 January 2008
Novartis' Zometa fares well vs Aredia
19 June 2006
Roche Bondronat: clarifications
29 March 2004
Zometa effective long-term, says CPMP
3 March 2003
Novartis sales grow 12% in 2nd qtr
29 July 2002
Australia's Mayne to sell Gensia drug
15 April 2002
Novartis gets OK for new Zometa use
4 March 2002
Double-digit turnover growth for Novartis in 2001
11 February 2002
Novartis' Zometa backed for treatment of bone metastases in USA
11 February 2002
Gensia Sicor's generic pamidronate OKed
30 November 2001
APP claims victory in Aredia dispute
28 November 2001
Update: Novartis files new indication for Gleevec in USA
24 October 2001
Novartis' Zometa finally wins FDA approval
22 August 2001
New Zometa indication filed with EMEA
8 August 2001
Novartis' Zometa gets European approval
30 March 2001
Novartis expects five new products to drive growth in 2001
15 February 2001
Novartis R&D day updates prospects for key pipeline drugs
7 December 2000
Novartis' Zometa cleared in Switzerland
7 December 2000
Novartis wins first approval for Zometa
30 August 2000
Novartis puts in solid 1st-half performance
21 August 2000
Novartis' Zometa designated for priority review by FDA
10 February 2000
Novartis seeks US, European Starlix OK
23 December 1999
Novartis Trileptal approvable in USA; firm building broad franchise in
30 September 1999
Novartis upbeat at biannual R&D update
23 September 1999
Novartis 1998 sales down on forecasts
21 January 1999
"Underlying Quality" In Novartis' Growth
2 November 1998
Pharma Sales Give Novartis Boost
22 October 1998
Novartis Restructures After Disappointing First Half
1 September 1998
Novartis First Half Sales Under Expectations
16 July 1998
Novartis' Exelon Cleared In First Major Market
14 May 1998
Modest Rise In Sales At Novartis Lower Than Expected
22 April 1998
First Operational Year Strong At Novartis
19 March 1998
Hycamtin Potential In Multiple Myeloma?
4 March 1998
Novartis' Nine-Month Drug Sales Climb 26%
30 October 1997
Strong Pharmaceutical Growth Drives Novartis
24 July 1997
US Quarterly Financial Results Round-Up
5 May 1997
Health Care Fuels Strong 1997 Start For Novartis
21 April 1997
Aredia For Bone Metastases From Breast Cancer
19 August 1996
Strong Growth From Ciba In 1996 First Half
22 July 1996
New Indication Approval For Ciba's Aredia
15 July 1996
Novartis Pipeline: A Good Fit But Cuts Are Expected
18 March 1996
Novartis Pipeline: A Good Fit But Cuts Are Expected
18 March 1996
Aredia - NEJM Study Published
26 February 1996
Ciba/Chiron's Aredia Gains New Indication In USA
18 September 1995
Sales Decline 6% At Ciba In 1995 First Half
4 September 1995
Ciba/Chiron's Aredia Backed By FDA Panel
7 August 1995
Ciba Reveals Pipeline With Broad Reach
17 April 1995
Silicone Oil Approval In USA
21 November 1994
Ciba Japan Launch
26 September 1994
CIBA RESULTS FOR 1993 "AS PROMISED"
4 April 1994
CANCER MEDICINES IN DEVELOPMENT
14 June 1993
CIBA'S 1st QTR COULD BE SLOWER THAN 1992 1st QTR
12 April 1993
CIBA LAUNCHES NEW AREDIA FORMULATION
15 February 1993
ANALYSTS ASSESS CIBA'S PHARMA PROSPECTS
9 November 1992
Showing 1-69 of 69 articles
- 1
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Italy's pharma market slump set to continue, warns GlobalData
- Pfizer to split-off remaining 80% interest in Zoetis
